ImmunoGen Announces Webcast of Presentation at the Canaccord Genuity Growth Conference
August 01 2017 - 4:30PM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a
leader in the expanding field of antibody-drug conjugates (ADCs)
for the treatment of cancer, today announced that David Johnston,
chief financial officer, will present at the upcoming Canaccord
Genuity Growth Conference. The presentation is scheduled for August
10, 2017 at 10am ET.
A webcast of the presentation will be accessible through the
Investors section of the Company's website, www.immunogen.com.
Following the live webcast, a replay will be available at the same
location for approximately two weeks.
About ImmunoGen, Inc.
ImmunoGen is a clinical-stage biotechnology company that
develops targeted cancer therapeutics using its proprietary ADC
technology. ImmunoGen's lead product candidate, mirvetuximab
soravtansine, is in a Phase 3 trial for FRα-positive
platinum-resistant ovarian cancer, and is in Phase 1b/2
testing in combination regimens for earlier-stage disease.
ImmunoGen's ADC technology is used in Roche's marketed product,
Kadcyla®, in other clinical-stage ImmunoGen product candidates, and
in programs in development by Amgen, Bayer, Biotest, CytomX,
Debiopharm, Lilly, Novartis, Sanofi and Takeda. More information
about the Company can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the
Roche Group.
This press release includes forward-looking statements. For
these statements, ImmunoGen claims the protection of the safe
harbor for forward-looking statements provided by the Private
Securities Litigation Reform Act of 1995. It should be noted that
there are risks and uncertainties related to the development of
novel anticancer products, including mirvetuximab soravtansine,
including risks related to preclinical and clinical studies, their
timings and results. A review of these risks can be found in
ImmunoGen's Annual Report on Form 10-K for the fiscal year
ended December 31, 2016 and other reports filed with
the Securities and Exchange Commission.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170801006700/en/
For InvestorsImmunoGen, Inc.Sarah Kiely,
781-895-0600sarah.kiely@immunogen.comorFor MediaImmunoGen,
Inc.Courtney O’Konek,
781-895-0600courtney.okonek@immunogen.comorFTI Consulting
Inc.Robert Stanislaro,
212-850-5657robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024